Evidence map›Paper›PMID 31841390›Full record

ArticleAmerican journal of physiology. Renal physiology2020

COX-2-derived prostaglandins as mediators of the deleterious effects of nicotine in chronic kidney disease.

S Rangarajan, G Rezonzew, P Chumley, H Fatima, M Y Golovko, W Feng, P Hua, E A Jaimes

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Nicotine, smoking, podocytes, and diabetic nephropathy.American journal of physiology. Renal physiology · 2021
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

S RangarajanRenal Division, University of Alabama at Birmingham, Birmingham, Alabama.
G RezonzewRenal Division, University of Alabama at Birmingham, Birmingham, Alabama.
P ChumleyRenal Division, University of Alabama at Birmingham, Birmingham, Alabama.
H FatimaDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
M Y GolovkoDepartment of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota.
W FengRenal Division, University of Alabama at Birmingham, Birmingham, Alabama.
P HuaRenal Division, University of Alabama at Birmingham, Birmingham, Alabama.
E A JaimesRenal Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
University of Alabama at Birmingham · USCornell University · USUniversity of North Dakota · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Pilot Projects CoreP30GM103329 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI GEIGER, JONATHAN DAVID · 2012 to 2016
$5.1M
Nicotine and Chronic Kidney DiseaseR01ES014948 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JAIMES, EDGAR A · 2009 to 2010
$1.1M
NCI NIH HHS P30 CA008748NIEHS NIH HHS R01 ES014948NIGMS NIH HHS P30 GM103329
6 · The paper itself

Abstract

Tobacco smoking has been identified as a risk factor in the progression of chronic kidney disease (CKD). In previous studies, we showed that nicotine induces cyclooxygenase (COX)-2 expression in vivo and in vitro and that the administration of nicotine in vivo worsens the severity of renal injury in a model of subtotal renal ablation. In the present study, we tested the role of COX-2-derived prostaglandins on the deleterious effects of nicotine in CKD. Sham and 5/6 nephrectomy (5/6Nx) rats received tap water or nicotine (100 μg/mL) in the drinking water for 12 wk. Additional groups also systemically received the COX-2 inhibitor NS-398 (1.5 mg·kg

Indexed as

AnimalsCyclooxygenase 2Cyclooxygenase 2 InhibitorsDinoprostDinoprostoneDisease Models, AnimalDown-RegulationEpoprostenolKidneyLow Density Lipoprotein Receptor-Related Protein-2MaleNephrectomyNicotineNicotinic AgonistsProstaglandin D2ProstaglandinsCyclooxygenase 2Cyclooxygenase 2 InhibitorsDinoprostDinoprostoneEpoprostenolLow Density Lipoprotein Receptor-Related Protein-2Lrp2 protein, ratNicotineNicotinic AgonistsProstaglandin D2ProstaglandinsPtgs2 protein, ratThromboxane A2chronic kidney diseasecyclooxygenasenicotineprostaglandinssmoking

Identifiers

PMID31841390
PMCPMC7052654
OpenAlexW2995546034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.